A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Concizumab (Primary)
- Indications Haemophilia
- Focus Adverse reactions
- Acronyms Explorer 2
- Sponsors Novo Nordisk
- 29 Apr 2014 New trial record
- 08 Jan 2014 According to ClinicalTrials.gov record, the status has changed from suspended to terminated due to the need for changes in the trial design requiring a new re-designed multiple dosing phase 1 trial.
- 27 Sep 2012 According to ClinicalTrials.gov record, the status has changed from recruiting to suspended while awaiting protocol amendment.